Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trial-Reference-Cited by-同舟云学术

Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trial

Published:2023-08 Issue:8 Volume:42 Page:1140-1151
ISSN:1053-2498
Container-title:The Journal of Heart and Lung Transplantation
language:en
Short-container-title:The Journal of Heart and Lung Transplantation

Author:

Zhang Juan,Kan Jing^ORCID,Wei Yongyue^ORCID,Zhang Caojin,Yang Zhenwen,Gu Heping,Fan Fenling,Gu Hong,Wang Qiguang,Xie Dujiang,Zhang Gangcheng,Guo Xiaomei,Yin Yuehui,Jin Bowen,Zhou Hongmei,Yang Ziyang^ORCID,Wang Zhouming,Xin Yu^ORCID,Zhang Chen,Meng Lili,Wang Xiaoyu,Zhao Chunxia,Zhang Hang,Yan Xiaoyan,Chen Feng,Yao Cheng,Benza Raymond L.^ORCID,Stone Gregg W.,Chen Shao-Liang^ORCID

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Transplantation,Cardiology and Cardiovascular Medicine,Pulmonary and Respiratory Medicine,Surgery

Reference22 articles.

1. Diagnosis of pulmonary hypertension;Frost;Eur Respir J,2019

2. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension;Humbert;Eur Respir J,2022

3. The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension;Benza;Chest,2012

4. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-Based risk assessment strategies;Benza;Chest,2019

5. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model;Hoeper;Eur Respir J,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pulmonary hypertension and chronic kidney disease: prevalence, pathophysiology and outcomes;Nature Reviews Nephrology;2024-06-18

2. A sham-controlled randomised trial of pulmonary artery denervation for Group 1 pulmonary arterial hypertension: one-year outcomes of the PADN-CFDA trial;EuroIntervention;2023-10